a Halcyon linac with Hypersight at CCC-Liverpool
A second state-of-the art machine to deliver radiotherapy treatment to people with cancer is on it's way to The Clatterbridge Cancer Centre following a successful funding bid.
Later this year, Clatterbridge Cancer Centre - Liverpool will receive a new Varian Halcyon linear accelerator (or linac) with Hypersight technology, the second machine of its kind at the centre. The new linac has been made possible thanks to a £2.9million grant from the National Radiotherapy Replacement Fund, a government scheme announced in October 2024 to invest £70million in replacing old radiotherapy machines in a bid to cut waiting lists.
The new machine will replace a current linac named Hawthorn and will offer improved technology to aid efficiency and enhance patient experience.
Louise Bagley is Physics General Manager at The Clatterbridge Cancer Centre and was part of the team leading the bid. She says: "We're delighted to be one of the centres that has been awarded funding for a new linac. Our other Varian Halcyon with Hypersight was delivered in January this year and began treating patients a few weeks ago, thanks to lots of hard work from various teams across the Trust.
"This new machine, which we expect will arrive on-site at the end of the year and will be ready to treat patients by March 2026, will allow us to increase capacity and treat more patients, with an improved experience, so we can continue to meet demand. It’s a really exciting development for Clatterbridge and will have huge benefits to the people we care for.”
